Vasculox Changes Name, Raises $86M and Hires New CEO
“Tioma Therapeutics, a St. Louis-based pharmaceutical discovery startup formerly known as Vasculox, has raised an $86 million Series A led by Clayton-based RiverVest Venture Partners.
The company also announced that John Donovan has been hired as the company’s president and CEO. Donovan, who also sits on Tioma’s board of directors, previously served as co-founder and CFO of Alios BioPharma, which was acquired by Johnson & Johnson in 2014 for $1.75 billion.”
Read full St. Louis Business Journal article here.